<DOC>
	<DOCNO>NCT01630057</DOCNO>
	<brief_summary>An open-label , randomize , multi-centre , superiority study ass , patient respond zonisamide added third drug failure two-drug combination therapy , triple therapy superior conversion double therapy include zonisamide .</brief_summary>
	<brief_title>Evaluation Efficacy Safety Adjunctive Zonisamide v Replacement With Zonisamide Last Added Antiepileptic Drug</brief_title>
	<detailed_description />
	<mesh_term>Seizures</mesh_term>
	<mesh_term>Zonisamide</mesh_term>
	<mesh_term>Anticonvulsants</mesh_term>
	<criteria>Patients localizationrelated epilepsy , add second drug monotherapy , n't obtain adequate reduction seizure frequency combination respond zonisamide added third drug least three month . Inclusion criterion : Age â‰¥ 18 year ; Patients non progressive localizationrelated epilepsy ; Patients able willing give write Informed Consent ; Current treatment three antiepileptic drug . The last antiepileptic drug introduce must zonisamide ; 50 % great seizure reduction* assess least threemonth maintenance period zonisamide . = seizure frequency start zonisamide must document check case history . Exclusion criterion : Patients contraindicate zonisamide use ( see SmPC ) ; Patients renal hepatic impairment ; Pregnant lactate woman ; Women childbearing age willing use contraceptive method establish efficacy . Patients suffer clinically significant psychiatric illness , psychological behavioral problem could interfere study participation ; Patients history ( within last 12 month ) alcohol drug abuse dependency ; Patients investigational drug device within 30 day prior initiation present study ; Patients document computed axial tomography ( CAT ) scan magnetic resonance imaging ( MRI ) scan confirm presence progressive neurological lesion within 12 month screen visit .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>July 2014</verification_date>
</DOC>